1-3 of 3
Blake Pond, MS
Close
Sort by
Journal Articles

Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

Haijiao Zhang, MD, Kevin Matthew Watanabe-Smith, BS, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, Hagop M. Kantarjian, MD, Judy Ho, Jeremy Davis, Blake Pond, MS, Gautam Borthakur, MD, Abhijit Ramachandran, MS, Jorge E. Cortes, Robert Collins, MD, Jeffrey W. Tyner, PhD
Journal: Blood
Blood (2015) 126 (23): 2468.
https://doi.org/10.1182/blood.V126.23.2468.2468
Published: 2015
Journal Articles

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

John Carl Panetta, Sharyn D Baker, PharmD, PhD, Hagop M. Kantarjian, MD, Clinton Stewart, Pharm.D., Blake Pond, MS, Meghan Macaraeg, BS, Tolu Makinde, PhD, Sheetal Vali, PhD, Naval Daver, MD, Abhijit Ramachandran, MS, Robert Collins, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2015) 126 (23): 3695.
https://doi.org/10.1182/blood.V126.23.3695.3695
Published: 2015
Journal Articles

Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant

Robert Collins, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Jenny Chen, MDPhD, Meghan Macaraeg, BS, Vinoo Urity, MS, Blake Pond, MS, Abhijit Ramachandran, MS, Jorge E. Cortes, MD
Journal: Blood
Blood (2015) 126 (23): 4359.
https://doi.org/10.1182/blood.V126.23.4359.4359
Published: 2015